Owners’ Experience and Satisfaction with Radioiodine Treatment in Hyperthyroid Cats—A Prospective Questionnaire Study

Radioiodine (RAI) treatment (RAIT) is considered the gold standard for treatment of feline hyperthyroidism. This study aimed to assess owners' motivation, concerns and satisfaction with RAIT and health-related quality of life (HRQoL) changes in RAI-treated cats. Two surveys (before and six months post-RAIT) were sent to owners of cats scheduled for RAIT between April 2023 and March 2024. The owners of 78 and 68 cats completed the first and the second surveys, respectively. The main reasons for choosing RAIT were that RAIT was considered the gold standard treatment (<i>n</i> = 27/78; 35%) and difficulties administering antithyroid drugs (<i>n</i> = 18/78; 23%). The primary care veterinarian (<i>n</i> = 50/78; 64%) and the internet (<i>n</i> = 33/78; 42%) were the main information sources about RAIT at the referral clinic. Owners were mostly concerned about the anaesthetic risk and hospitalisation, with the cat missing the owner and vice versa being the main worries. Most owners were satisfied with the outcome and their decision for RAIT. The HRQoL score improved within the first six months after RAIT (<i>p</i> < 0.01), with no difference between euthyroid and hypothyroid cats (<i>p</i> = 0.609). This study emphasises the role of the primary care veterinarian and the internet as primary sources of information regarding RAIT. The findings help to better understand owner concerns, improve owner counselling, and educate primary care veterinarians about RAIT.